**Invasive Enterobacter sakazakii Disease in Infants**

Anna B. Bowen* and Christopher R. Braden*

---

*Centers for Disease Control and Prevention, Atlanta, Georgia, USA*

---

**Enterobacter sakazakii** kills 40%–80% of infected infants and has been associated with powdered formula. We analyzed 46 cases of invasive infant *E. sakazakii* infection to define risk factors and guide prevention and treatment. Twelve infants had bacteremia, 33 had meningitis, and 1 had a urinary tract infection. Compared with infants with isolated bacteremia, infants with meningitis had greater birthweight (2,454 g vs. 850 g, \( p = 0.002 \)) and gestational age (37 weeks vs. 27.8 weeks, \( p = 0.02 \)), and infection developed at a younger age (6 days vs. 35 days, \( p < 0.001 \)). Among meningitis patients, 11 (33%) had seizures, 7 (21%) had brain abscess, and 14 (42%) died. Twenty-four (92%) of 26 infants with feeding patterns specified were fed powdered formula. Formula samples associated with 15 (68%) of 22 cases yielded *E. sakazakii*; in 13 cases, clinical and formula strains were indistinguishable. Further clarification of clinical risk factors and improved powdered formula safety is needed.

**Methods**

We reviewed the literature for reports of *E. sakazakii* disease in infants. Using medical subject heading terms “*E. sakazakii*” or “Enterobacter” in combination with “newborn,” “infant,” or “meningitis,” we searched PubMed and examined the bibliographies of resulting articles. Finally, we reviewed *E. sakazakii* case consultations conducted by the Centers for Disease Control and Prevention (CDC) from 1998 to 2005 and reviewed results of a French outbreak reported to CDC in 2005 (14).

We defined a case as an infant (<12 months of age) with *E. sakazakii* cultured from an area of the body that is normally sterile: tissue, blood, cerebrospinal fluid, or urine aspirated through the bladder wall. Infants with cultures of cerebrospinal fluid or brain abscesses yielding *E. sakazakii* were considered to have meningitis. Because bacteremia is usually an intermediate step during the process of developing meningitis, patients with both bacteremia and meningitis were included in the meningitis group. Bacteremia was defined as *E. sakazakii* grown from the blood of a case-patient without evidence of meningitis.

Infants with gestational ages <37 weeks, or those reported to be premature, were considered premature. A gestational age of 40 weeks was assigned to 3 (27%) of 11 infants with bacteremia and 4 (14%) of 28 infants with meningitis who were reported as born following term gestation without a specific gestational age mentioned. We defined birthweight <2,500 g as low birthweight (LBW), <1,500 g as very low birthweight (VLBW), and <1,000 g as extremely low birthweight (ELBW).

Descriptive analysis was performed by using SAS software (SAS Institute, Cary, NC, USA). Groups were compared by using 2-tailed Fisher exact test.

**Results**

Forty-six infants met the case definition (Table 1). Reported onset years ranged from 1958 to 2005; 32 (70%) cases were reported during the second half of this period.
Cases were reported in 7 countries in North America, Europe, and the Middle East. Thirty-three (72%) infants had meningitis, 12 (26%) had bacteremia, and 1 (2%) had a urinary tract infection.

Clinical characteristics were available for a subset of cases (Table 2). Eight (40%) of 20 infants for whom data were available were delivered by cesarean section. Twenty-nine (69%) of 42 infants experienced disease onset within a hospital. Gestational duration was available for 38 infants; 21 (55%) were born prematurely, and the median gestational age overall was 36 weeks (range 23.5–40 weeks). The median birthweight was 2,063 g (range 540–3,401); 18 (56%) of 32 infants had LBW; 9 (28%) of these met the definition for VLBW, and 7 (22%) met the definition for ELBW. Median age at the time of infection onset was 8.5 days (range 2–300).

Although the proportion of infants who experienced nosocomial disease onset was not significantly different between the meningitis and bacteremia groups, other infant characteristics differed by site of infection (Figure). The median gestational ages of infants with meningitis and bacteremia were 37 and 27.8 weeks, respectively (p = 0.02). Median birthweights were 2,063 g (range 540–3,401); 18 (56%) of 32 infants had LBW; 9 (28%) of these met the definition for VLBW, and 7 (22%) met the definition for ELBW. Median age at the time of infection onset was 8.5 days (range 2–300).

Although numerous reports include infants with *E. sakazakii* isolated from nonsterile sites, such as respiratory secretions or stool, 46 infants identified from the literature and CDC sources met the case definition for this analysis (1,9,10,12). Of the infants with sterile-site infection, 72% had meningitis. Contrary to previous characterizations of *E. sakazakii* disease, we found that infants with meningitis and bacteremia alone fell into 2 distinct groups. Those in whom meningitis developed tended to be of greater gestational age and birthweight than those with bacteremia alone. In contrast, infants in whom bacteremia alone developed tended to be born very prematurely and have ELBW. A second major difference between the group with meningitis and the group with bacteremia was the infants’ chronological ages. Infants with meningitis were generally <1 week of age at the onset of infection with *E. sakazakii*, whereas infants with bacteremia had generally surpassed the neonatal period at the onset of their disease. Rates of adverse outcome also differed between the 2 groups, although this was not unexpected. Most infants with...
E. sakazakii bacteremia fared better than those with meningitis. Among those in whom meningitis developed, rates of adverse outcome were similar to those reported in the literature: In this case series, 74% of meningitis survivors experienced an adverse neurologic outcome, while other studies cite adverse outcome in 20%–78% of neonatal or infant meningitis survivors (21–23).

The division of the infant population into 2 distinct groups occurred for unclear reasons. That infants <1 week of age comprised the meningitis group was not surprising; the disparities in other infant characteristics, however, are not intuitive. Since infants in the 2 groups experienced similar rates of nosocomial disease onset, the infants with bacteremia were unlikely to have simply received treatment earlier in the disease course than the infants with meningitis. Other risk factors are probable.

One likely set of risk factors is infant formula-feeding practices. Powdered infant formula is a demonstrated source of E. sakazakii infection. A microbiologic survey of powdered infant formulas published in 1988 found E. sakazakii in 20 (14%) of 141 samples tested (24). However, a survey of 82 powdered infant formula samples in 2003 yielded E. sakazakii in 2 (2.4%), which suggests that recent rates of powdered formula contamination may be lower (25). Powdered formula has also been implicated both epidemiologically and microbiologically as a vehicle in several cases of E. sakazakii disease in infants (1,3,9,10,13). Although we could not explore feeding exposures fully with the data available in this series, infant feeding practices may relate to the differences we describe in chronological age of infants at onset of meningitis and bacteremia. Infants with nearly normal gestational ages and birthweights are likely to be tended in normal newborn nurseries during the first 24–72 hours of life. In such nurseries, powdered formula is frequently given to babies who are not breast-fed, and it may also be used as a supplement by mothers who have chosen to breast-feed. Since infants are at highest risk for meningitis during the first several weeks of life, possibly because of immaturity of the blood-brain barrier, exposures to E. sakazakii in powdered formula or other sources during this time may quickly lead to central nervous system disease (26,27).

Conversely, in the intensive care settings where immature and low birthweight infants are tended, babies are not often fed powdered formula in the first few weeks of life. They may be given parenteral nutrition initially and may be fed breast milk from their own mothers or from a banked source when they do begin enteral feeds. If breast milk is not available, they are more likely to be given sterile, premixed infant formula than powdered formula, since standard preterm infant formula is only available in this form (28). Powdered breast milk fortifiers are not introduced until premature infants tolerate full-volume feeds,
which may not occur for days or weeks after birth. Thus, infants in intensive care settings may not be exposed to nonsterile formula until they are more mature, which would lead to a greater proportion of E. sakazakii bacteremia than meningitis in this group if powdered formula is a source of infection. In this series, we were unable to explore the roles of indwelling enteric tubes, prior gastrointestinal surgery, and antecedent antacid or antimicrobial drug use as risk factors for infection.

While the reservoir for E. sakazakii is unknown, several environmental sources have been reported. E. sakazakii has been isolated from factories used to produce milk powder, chocolate, cereal, potato flour, spices, and pasta (29). It also has been isolated from household vacuum cleaner bags and from the guts of the stable fly, Stomoxys calcitrans, and the Mexican fruit fly, Anastrapha ludens (29–31). The relationship between these potential environmental sources and infant disease remains unclear. Although a human vaginal tract culture yielding E. sakazakii has been reported, vertical transmission is unlikely because nearly half of infants with E. sakazakii disease in this review were delivered by cesarean section and symptoms developed in only 1 infant earlier than 3 days of age (32).

Our analyses were constrained by the use of retrospective and often incomplete data. Although cases with more severe outcomes might have been investigated and published more frequently than uncomplicated cases, this possible bias would not likely affect the representativeness of baseline infant characteristics. Assigning a gestational age of 40 weeks to term infants without a reported gestational age may have falsely elevated the median gestational ages we report, since most term infants are born at <40 weeks’ gestation (33). However, a greater proportion of bacteremic infants than meningitic infants received this assignment, and therefore the significance of the differences in gestational age between the groups may be even greater than we report. We were unable to explore the effects of concomitant medical problems, treatments, and other environmental factors, and we relied on existing reports of feeding practices and formula testing. Clearly, additional study is needed to elucidate the lingering questions about this illness. Manufacturer warning labels on powdered infant formula packages should stress that powdered infant formula is nonsterile and requires proper preparation, handling, and storage, and that sterile, liquid formula alternatives are available. These actions, adopted in whole or in part, may decrease the infectious risks associated with powdered formula and prevent this rare but potentially devastating disease.

Acknowledgments
Thanks to L. Clifford McDonald, Matthew Kuehnert, and R. Mike Hoekstra for their unflagging technical support and to Matthew Arduino, Terri Forster, and Bette Jensen for sharing their laboratory expertise.

Dr Bowen is a medical epidemiologist in the Foodborne and Diarrheal Diseases Branch at CDC. Her primary research interests include global infant feeding safety, hygiene, sanitation, and diarrheal diseases in the developing world.

Dr Braden is a medical epidemiologist in the Foodborne and Diarrheal Diseases Branch at CDC. His main areas of interest are the surveillance and epidemiology of foodborne diseases.

References
Invasive Enterobacter sakazakii in Infants


Address for correspondence: Anna B. Bowen, Foodborne and Diarrheal Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Rd, Mailstop A38, Atlanta, GA 30333, USA. email: abowen@cdc.gov

Use of trade names is for identification only and does not imply endorsement by the Public Health Service or by the U.S. Department of Health and Human Services.

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.